Five pediatric patients are described with acute lymphoblastic leukemia (ALL) who at presentation had clinical findings suggestive of B cell ALL and lymphoblasts with FAB L3 morphology and the characteristic t(8;14)(q24;q32). However, the leukemia cells of all five patients failed to express surface immunoglobulin (sIg) and kappa or lambda light chains. Based on initial immunophenotyping results consistent with B-precursor ALL, four of these cases were initially treated with conventional ALL chemotherapy. These four patients were switched to B cell ALL treatment protocols once cytogenetic results became available revealing the 8;14 translocation. The fifth case was treated with B cell ALL therapy from the outset. Four of the five patients are in complete remission at 64, 36, 29 and 13 months from diagnosis. One patient relapsed and died 6 months after initial presentation. These five unusual cases with clinical B cell ALL, the t(8;14), and FAB L3 morphology, but negative sIg, demonstrate the importance of careful and multidisciplinary evaluation of leukemic cells with morphology, cytochemistry, immunophenotyping and cytogenetic analysis. Future identification of patients with this profile will allow us to expand our knowledge regarding prognostic significance and optimal treatment for this rare subgroup of patients.
Introduction
Since its first description in the 1970s, B cell acute lymphoblastic leukemia (B cell ALL) has been recognized for its poor response to conventional ALL therapy. 1 It was eventually noted however, in contrast to patients with B-precursor ALL, that B cell ALL patients did better with extremely intensive chemotherapy of short duration, employing agents like highdose cyclophosphamide/ifosfamide, high-dose intravenous methotrexate, epipodophyllotoxins, and cytarabine in addition to anthracyclines and vinca alkaloids. [2] [3] [4] [5] Classically, B cell ALL is characterized by L3 French-American-British (FAB) lymphoblast morphology, surface expression of immunoglobulin heavy chain (sIg), monoclonal kappa () or lambda () light chain expression, and the non-random chromosomal translocation t(8;14)(q24;q32) or, less commonly, a t(2;8)(p12;q24) or a t(8;22)(q24;q11). Not all patients with B cell ALL present with all the classic findings, either because of biologic variability, 2 or because of limitations in diagnostic techniques. However, the presence of sIg, with clonal or light chain expression, has been considered essential to the diagnosis of B cell ALL.
We report five unusual cases of acute lymphoblastic leukemia. Because of immunophenotyping results consistent with B-precursor ALL, four of these cases were initially treated with conventional ALL chemotherapy on Pediatric Oncology Group (POG) protocols, although clinical findings and blast cell morphology were suggestive of B cell ALL. These four patients were subsequently switched to B cell ALL treatment once cytogenetic results became available. The fifth case was treated with B cell ALL type therapy from the outset.
Methods
The five cases described were identified out of a total of 5280 ALL patients evaluated by the POG from January 1991 to August 1997 on the POG 9000 and 9400 classification studies (Pullen, personal communication, August 1997). These five patients were evaluated and treated at five different POG institutions. All patients had leukemic cell classification studies performed prior to initiation of therapy as registrants on the POG 9000 or 9400 new ALL classification studies. Negative Sudan black and/or peroxidase stains and negative nonspecific esterase staining of blasts were required in order for patients to be eligible for the POG new ALL classification studies. Blast cell FAB classification was reviewed centrally in cases that were diagnostic problems.
Immunophenotyping was performed at the Johns Hopkins reference laboratory by two or three color fluorescence flow cytometry as previously described. 6 For surface immunoglobulin testing performed in the reference laboratory, aliquots of bone marrow were first washed twice in phosphate-buffered saline to remove any cytophilically bound antibody, and then incubated with a mixture of fluorescein-conjugated anti-kappa and phycoerythrin-conjugated anti-lambda (Becton Dickinson, San Jose, CA, USA), and analyzed on a FACScan flow cytometer. In these cases the majority of the blast population could be identified as being negative for both light chains, while a small population of residual B cells expressing a mixture of kappa and lambda positive cells could be identified. For all but one of the remaining cases, flow cytometry results [4] from local institutions were reviewed by one of us (MJB). In these cases, immunoglobulin staining was performed by dual color analysis using CD19-PE and either FITC-conjugated antikappa or anti-lambda antibodies. In two of these cases, normal residual polyclonal B cells could also be recognized, while the blast population was clearly negative for each light chain.
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A summary of clinical and laboratory data, and pertinent flow cytometry results, are given in Tables 1 and 2 , respectively.
Case reports

Case 1
A white female of 3 years and 11 months presented with a 1 week history of cough, rhinorrhea, fatigue, dental pain, bruising and petechiae. Physical examination showed lymphadenopathy and marked hepatosplenomegaly. Initial laboratory results showed hemoglobin 11.4 g/dl, white blood cell count 33 000/mm 3 (41% blasts), platelet count 9000/mm 3 , uric acid 14 mg/dl, and LDH 30 109 U/l. The cerebrospinal fluid was negative for leukemic blasts. The bone marrow showed blasts with an atypical FAB L3 morphology ( Figure 1a ). Immunophenotyping was consistent with B-precursor ALL (see Table  2 ). There was no expression of sIg, or light chains, and as is often seen in B-precursor ALL, CD20 was negative. The patient was enrolled on the standard risk POG protocol for Bprecursor ALL and begun on three-drug induction with vincri- Table 2 Summary of immunophenotype of leukemic cells in the five cases Case CD10 CD19 CD20 CD34 TdT -ik/ polyv sIg cIgMu a No. stine, prednisone, and L-asparaginase. Cytogenetic studies subsequently revealed the t(8;14)(q24;q32). Based on the cytogenetic findings, the patient was switched to a previously described POG regimen for B cell ALL. 3 She tolerated chemotherapy well and currently continues in remission 64 months from diagnosis.
Case 2
A 14-year-old white male presented with a 1 month history of fatigue, gradual facial swelling and right-sided flank pain. Physical examination was remarkable for marked bilateral anterior cervical lymphadenopathy and a palpable spleen tip. Initial laboratory results showed hemoglobin 11.9 g/dl, platelets 27 000/mm 3 white blood cells 8300/mm 3 , uric acid 17 mg/dl, and LDH 10 629 U/l. The cerebrospinal fluid was negative for leukemic cells. Abdominal CT revealed splenomegaly with multiple low density nodules in both kidneys suggesting tumor infiltrates. The bone marrow was replaced with predominantly FAB L3 lymphoblasts ( Figure 1b) . However, the blast cells did not express sIg, or , and lacked mature B cell markers, and was positive for TdT, most consistent with B-precursor ALL (Table 2 ). Based on this diagnosis, standard induction treatment with vincristine, prednisone, and L-asparaginase was begun. Cytogenetic studies subsequently showed the t(8;14)(q24;q32). Based on this finding plus the L3 morphology and high uric acid and LDH at initial presentation, the patient was switched to an aggressive B cell ALL POG treatment protocol. Complete remission was achieved by day 35. Three weeks after completing all prescribed therapy, the patient presented with a subcutaneous mass in the temporal region and frank marrow relapse characterized by blasts with immunophenotypic markers identical to those at diagnosis. Reinduction therapy was unsuccessful and the patient died 4 weeks later (6 months from the time of his original diagnosis).
Case 3
A 13-year-old white female presented with a 1. week history of fever, joint pain, bruising, intermittent emesis and epistaxis. Physical examination showed hepatosplenomegaly, purpura and petechiae. Initial laboratory studies included hemoglobin 14 g/dl, white blood cells 20 000/mm 3 (25% blasts), platelets (Table 2) . She underwent standard four-drug induction for B-precursor ALL with prednisone, vincristine, L-asparaginase and daunorubicin. However, cytogenetic analysis revealed a t(8;14)(q24;q32). Based on these cytogenetic findings, the patient was taken off study and treated according to the current POG regimen for B cell ALL. She remains alive and disease-free 36 months from the time of diagnosis.
Case 4
A 14-year-old female presented with flu-like symptoms, dental pain, arthralgias and bruising. Physical examination was remarkable for ecchymoses and scattered petechiae, but no lymphadenopathy or hepatomegaly. Her laboratory evaluation showed hemoglobin 15.4 g/dl, white blood cells 50 300/mm 3 (26% blasts), platelets 63 000/mm 3 uric acid 11.7 mg/dl, and LDH 21 432 U/l, and SGOT 208 U/l. Abdominal ultrasound was normal except for splenomegaly (16.9 cm). Cerebrospinal fluid was negative for leukemic cells. Bone marrow aspirate and biopsy revealed 64% blasts. Morphologically the blasts were considered to be FAB L3 ( Figure  1d ). Immunophenotyping showed results suggestive of pre-B ALL ( Table 2 ). The blasts were negative for sIg and for and light chain expression, but did have cytoplasmic heavy chain expression (cIgMu). Cytogenetic results showed the t(8;14)(q24;q32). Despite the absence of surface immunoglobulin, she was considered to have B cell ALL based on her cytogenetic study results and was treated according to the current B cell ALL POG protocol. She tolerated chemotherapy well and currently continues in remission 29 months from diagnosis.
Case 5
A 6-year-old white male presented with a 2-3 weeks history of right periorbital swelling, headache and fever. Physical examination was remarkable for right greater than left periorbital swelling. There was no significant adenopathy or hepatosplenomegaly. CT scan and MRI of the head demonstrated periorbital edema consistent with preseptal cellulitis, as well as right maxillary sinus disease. CT scans of the chest and abdomen revealed no masses. The initial laboratory results showed: hemoglobin 8.6 g/dl, white blood cells 12 700/mm 3 (31% blasts) and platelets 92 000/mm 3 uric acid 9.9 mg/dl and LDH 5090 U/l. The cerebral spinal fluid was negative for leukemic cells. Bone marrow aspirate was hypercellular with 66% blasts that were consistent with L3 morphology (Figure  1e ). Immunophenotype was consistent with B-precursor ALL, with TdT positivity, although the cells did express CD20 (Table 2 ). Based upon the immunophenotype and bone marrow morphology, the child was diagnosed with B-precursor ALL, and begun on standard three-drug induction with vincristine, prednisone and L-asparaginase. On day 6 of induction therapy, the results of cytogenetics studies revealed t(8;14)(q24;q32). Based upon the clinical presentation and cytogenetics, therapy was switched to aggressive B cell ALL therapy, according to the current POG protocol. He tolerated chemotherapy well and currently continues in remission 13 months from diagnosis.
Discussion
B cell ALL or Burkitt leukemias comprise 1-2% of pediatric ALL. Despite the low incidence of this type of leukemia and its poor response to conventional treatment for B-precursor ALL, we have come to recognize over the past decade that patients with B cell ALL have an improved survival when treated with very intensive chemotherapy. 3, 4, 5, 7 Since the treatment strategy for patients with B cell ALL is different from other childhood leukemias, identifying this subset of patients plays an important role in management and outcome.
The five patients reported represent a diagnostic dilemma. With exception of the immunophenotype of the blast cells, all five cases had clinical and laboratory features consistent with B cell ALL. Marked elevations of LDH and uric acid were seen at presentation in all five patients. Interestingly, four of the five had facial symptoms described in B cell ALL. 8 All patients had the classic t(8;14)(q24;q32) seen in Burkitt's leukemia/ lymphoma. Four of the five patients had blasts with classic L3 morphology. One of the five was described to have blasts with atypical L3 morphology.
Generally, blasts with L3 morphology and translocations involving the myc oncogene on chromosome 8 demonstrate a mature B cell phenotype, with clonal expression of immunogobulin light chain. The cases in this study illustrate that this is not always the case. All five cases lacked surface membrane light chain expression. Our ability to detect small numbers of residual normal B cells in the majority of the cases makes it unlikely that the lack of surface membrane light chain expression was due to technical factors in the assay. Moreover, it is not just the lack of surface immunoglobulin expression, but the entire composite phenotype which differs from those typically seen in mature B cell leukemias. The phenotype most commonly associated with mature B cell malignancies is CD34-negative, TdT-negative, CD19 and CD20 brightly positive. 9 CD10 will be expressed on some though not all cases. Although our cases were all CD19-and CD10-positive, in other respects they were different. Two cases expressed CD34, which is not present on mature B cell leukemias, and three of the five cases were positive for TdT. CD20 expression was brightly positive in only one of the cases. Thus, the overall pattern of expression of surface antigens was that commonly associated with B-precursor leukemias. Only two of the five patients were tested for the presence of cIgMu. One of the two was found to be positive, suggesting overlap with the pre-B phenotype.
The fact that our five cases appear to be less differentiated by immunophenotyping than typical L3/B cell ALL cases suggests that factors other than dysregulation of MYC by t(8;14), t(2;8) or t(8;22) contribute to regulation of the level of differentiation of B-precursor cells with these translocations, or alternatively that dysregulation of MYC by these translocations can transform B precursor cells with a somewhat wider range of maturation than previously suspected. Our results demonstrate that a small percentage of B cell ALL cases are sIg-negative with less mature surface antigen expression than previously assumed.
In reviewing the pediatric literature, we found three patients with lymphoblastic leukemia who had the t(8;14)(q24;q32), absence of surface immunoglobulins, and variable mor-phology. [10] [11] [12] All three of these patients died within 6 months of diagnosis. One was a 10-year-old boy whose blasts had L1 morphology and expressed cytoplasmic immunoglobulin. He relapsed after treatment with standard ALL therapy. The leukemic cells at relapse were more consistent with L3, still carried the t(8;14), and were negative for sIg. The second patient was a 21-year-old man whose blasts had L2 morphology. He was treated with more intensive chemotherapy but died of resistant leukemia and sepsis 14 weeks after presentation. The third patient was a 15-year-old with blasts of L2 morphology and strongly positive TdT. He received 3 weeks of intensive chemotherapy with daunorubicin, vincristine, cyclophosphamide and steroids followed by maintenance chemotherapy of 6-MP, methotrexate and vincristine. He relapsed and died after a brief period of remission. The striking feature of these three cases is the aggressiveness and treatment resistance of the leukemia.
Although we are looking at a small number of patients, one might postulate that patients who possess a t(8;14)(q24;q32), regardless of the immunophenotype of the blasts, have more aggressive disease, and should be treated with intensive chemotherapy designed for B cell ALL. Our outcome data with the treatment of the five cases reported with L3-type treatment suggests that this choice is appropriate, and that therapeutically the cases behave similarly to standard B cell ALL. A previous report has described a case of L1/L2 ALL with clonal sIg but lacking the characteristic B cell translocation which had clinical behavior typical of B-precursor ALL, rather than L3/B cell ALL. 13 Therefore, in a hierarchy of clinical relevance of laboratory tests for diagnosis of B cell ALL, the three common translocations (t(8;14), t(2;8), and t(8;22)) are of greatest importance, correlate closely with L3 morphology, and correlate somewhat less well with clonal sIg expression.
The cases we report demonstrate the importance of evaluating patients with a combination of diagnostic tools in order to identify those who do not fit the recognized subgroups for a given disease. These five unusual patients, all with clinical B cell ALL, L3 morphology, and t(8;14)(q24;q32), but negative for sIg and for or light chain expression, represent only five such cases out of a total of 5280 ALL patients evaluated by POG during the same time period. Though this entity is a very rare occurrence, it should be noted that only 96 of these 5280 cases were diagnosed as B cell ALL and treated on B cell ALL protocols during this time period. Thus up to approximately 5% (five out of 96) of cases of L3 ALL with MYC translocations may have this aberrant phenotype. Future identification of patients with this profile based on complete and careful evaluation of leukemic cells with morphology, cytochemistry, immunophenotyping and cytogenetic analysis will allow us to gain a better understanding of the biology and prognostic significance of this rare subtype of acute lymphoblastic leukemia. 
Appendix: Participants in the Pediatric Oncology Group
Institution
Grant number
